Sedana Medical’s Nomination Committee established
Regulatory
According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2024 shall be composed of members appointed by the three largest shareholders as of September 30, along with the Chairman of the Board of Directors.
The composition of the Nomination Committee has now been established, and Sedana Medical today announces that the Nomination Committee for the 2024 Annual General Meeting consists of:
- Claus Bjerre, Chairman of the Board
- Karl Tobieson, appointed by Linc AB
- Patrik Walldov, appointed by Anders Walldov (including indirect holding via Brohuvudet AB)
- Monica Åsmyr, appointed by Swedbank Robur Fonder
The Nomination Committee represents 28,72 per cent of all voting rights in the company as of September 30, 2023. The Nomination Committee shall submit proposals for resolution by the 2024 General Meeting pertaining to the election of Chairman of the Meeting, fees and composition of the Board, auditors’ fees and the election of auditors and, if necessary, proposal for changes in the instruction to the Nomination Committee.
The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2024 and on Sedana Medical’s website, www.sedanamedical.com.
Shareholders wishing to submit proposals to Sedana Medical’s Nomination Committee can do so by sending an e-mail to info@sedanamedical.com (subject “Nomination Committee”) or by letter posted to Sedana Medical AB (publ), Attn: Sedana Medical Nomination Committee, Vendevägen 89, SE-182 32, Danderyd, Sweden. A proposal must reach the Nomination Committee no later than March 22, 2024, to be included in the notice to attend and the agenda for the annual general meeting.
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.